CATX Q1 EPS Decreased by Brookline Capital Management

Perspective Therapeutics, Inc. (NYSE:CATX) – Research analysts at Brookline Capital Management decreased their Q1 2025 earnings per share estimates for Perspective Therapeutics in a report issued on Wednesday, March 26th. Brookline Capital Management analyst K. Dolliver now anticipates that the company will post earnings per share of ($0.30) for the quarter, down from their previous forecast of ($0.29). Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($0.88) per share. Brookline Capital Management also issued estimates for Perspective Therapeutics’ FY2025 earnings at ($1.43) EPS, Q1 2026 earnings at ($0.46) EPS, Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.60) EPS and FY2026 earnings at ($2.07) EPS.

Several other analysts have also commented on the stock. Scotiabank started coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $15.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Perspective Therapeutics in a research note on Wednesday, March 19th. Royal Bank of Canada decreased their target price on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Thursday. Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a report on Thursday, March 6th. Finally, Cantor Fitzgerald raised Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $14.44.

Perspective Therapeutics Price Performance

Shares of NYSE CATX opened at $2.20 on Monday. Perspective Therapeutics has a twelve month low of $2.19 and a twelve month high of $19.05. The firm has a 50-day moving average of $2.94 and a two-hundred day moving average of $6.29.

Institutional Trading of Perspective Therapeutics

Large investors have recently modified their holdings of the company. FMR LLC boosted its holdings in Perspective Therapeutics by 3,994.9% during the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after acquiring an additional 5,370,392 shares during the period. Millennium Management LLC acquired a new position in shares of Perspective Therapeutics during the 4th quarter worth about $4,132,000. State Street Corp lifted its position in shares of Perspective Therapeutics by 119.6% during the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares during the last quarter. Octagon Capital Advisors LP boosted its stake in Perspective Therapeutics by 62.1% during the 4th quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock valued at $7,352,000 after purchasing an additional 882,528 shares during the period. Finally, Affinity Asset Advisors LLC grew its holdings in Perspective Therapeutics by 160.0% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock valued at $4,147,000 after buying an additional 800,000 shares during the last quarter. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.